腾讯网22 小时
开发潜在“first-in-class”单抗靶向自身免疫疾病，新锐获2亿美元融资
▎药明康德内容团队编辑Abcuro今日宣布完成总额达2亿美元的C轮融资，此轮融资由New Enterprise Associates（NEA）领投，ForesiteCapital参与，现有投资者包括RA ...
PipelineReview.com1 天
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in ...
NEWTON, MA, USA I 12, 2025 I Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and ...